Trump's 100% Pharmaceutical Tariff Hits Australia. The PBS Won't Move.

The United States placed a 100% tariff on pharmaceutical exports from Australia this week. The order targets a sector where Australia produces globally major volumes, including biologics and complex medications processed by companies such as CSL Behring.

The political response from Canberra was uniform. Health Minister Mark Butler told reporters the federal government was "not negotiating" when it came to removing PBS price protections. Communications Minister Anika Wells called the tariff decision "disappointing" but confirmed the PBS would not be touched. Opposition Leader Angus Taylor took the same position. Australia has bipartisan consensus: the Pharmaceutical Benefits Scheme is not a trade concession.

Why the US Is Targeting the PBS

The US Trade Representative's annual report on foreign trade barriers, released this week, named Australia's PBS specifically. The argument from the US side is that the PBS, which uses government bargaining power to set below-market prices for drugs listed on the scheme, subsidises Australian consumers at the expense of pharmaceutical company revenues. US drug makers argue they cannot recoup research and development costs at PBS-negotiated prices.

This complaint is not new. The original Australia-US Free Trade Agreement in 2004 included language about pharmaceutical pricing that the US pushed hard on and Australia resisted. The PBS survived that round of negotiations. It survived subsequent reviews. Honestly, the 100% tariff is a different kind of pressure, not a negotiating position in a treaty framework but a unilateral trade penalty.

CSL issued a statement saying the company was reviewing information from the US but did not anticipate material impact in the near term. CSL's primary US business involves plasma-derived therapies manufactured in the United States itself, which reduces its direct exposure to export tariffs. But the company's broader international operations are still being assessed.

The Numbers Behind Australian Pharmaceutical Exports

Australia exported approximately $3.5 billion worth of pharmaceutical products to the US in the year to March 2025, according to the Department of Foreign Affairs and Trade. A 100% tariff doesn't automatically halve that figure. Importers can absorb some costs, adjust product lines, or seek regulatory carve-outs. But a doubling of the effective import price is a serious barrier for any exporter competing in the world's largest pharmaceutical market.

The tariff applies to goods, not services. Australian pharmaceutical companies that operate US manufacturing facilities are insulated from the direct impact. The question is whether the tariff leads to renegotiated supply agreements, reduced volumes, or pushes US buyers toward domestic alternatives, particularly biosimilars, where American manufacturers are increasingly competitive.

What Happens Next

The government's position, PBS is not negotiable, is clear and politically unified. What isn't clear is whether the US will treat this as a permanent tariff or a negotiating chip. To be blunt: there is no obvious mechanism by which Australia satisfies the US demand. Removing PBS pricing would require legislation and would be politically catastrophic domestically.

Industry groups including Medicines Australia have called on the government to pursue the issue through the World Trade Organisation and bilateral channels. A WTO dispute process takes years. Bilateral negotiation, given current US trade posture, is unlikely to yield quick relief.

The pharmaceutical tariff arrives as Australian businesses are still adjusting to the year-old Liberation Day framework. For most sectors, the 10% base rate was manageable. A 100% tariff on a specific, high-value export sector is a different order of magnitude, and the political constraints on what Canberra can offer in return are binding.